Author(s)
Monreal M1, Agnelli G2, Chuang L3, Cohen AT4, Gumbs PD5, Bauersachs R6, Mismetti P7, Gitt AK8, Kroep S3, Willich SN9, van Hout B10
1Hospital Universitari Germans Trias I Pujol, Barcelona, Spain, 2University of Perugia, Italy, Perugia, Italy, 3Pharmerit International, Rotterdam, The Netherlands, 4Guy's and St Thomas' NHS Foundation Trust, London, UK, 5Daiichi-Sankyo Europe GmbH, Munich, Germany, 6Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt, Germany, 7Saint Etienne University Hospital, Saint Etienne, France, 8Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 9Charité - Universitätsmedizin Berlin, Berlin, Germany, 10University of Sheffield, Sheffield, UK
OBJECTIVES: Deep-vein thrombosis (DVT) and pulmonary embolism (PE; collectively termed venous thromboembolism [VTE]) are a major healthcare burden in Europe, but exact estimates of this burden are lacking. This study reports results from the PREFER study concerning mortality and quality of life of DVT patients. METHODS: The PREFER in VTE registry was a prospective, observational, multicenter study, carried out in seven European countries, designed to provide data concerning treatment patterns, resource utilization, mortality and quality of life. Data was available for 2,056 patients with a first-time and/or recurrent DVT with follow up documentation at 1, 3, 6 and 12 months. Survival was analyzed using logistic regression, assessing the impact of baseline characteristics with a breakdown in cancer and non-cancer patients. Quality of life - as measured by EQ-5D-5L – was analyzed using the similar variables applying a repeated measures tobit regression. RESULTS: In DVT patients with a mean age of 60 years, 42.9% with active cancer and 4.7% of those without active cancer died within a year. Higher age, the presence of liver disease and lower BMI were significant predictors in both groups. Additionally, smoking history, previous AF, major surgery, varicose veins or bed rest >5 days were significant predictors in the non-cancer group. Average quality of life improved from baseline to 12 months in both the cancer (from 0.72 to 0.87) and non-cancer group (0.70 to 0.79). When scoring non-survivors at zero, average quality of life decreased in the cancer group to 0.55 at 12 months. Higher age, BMI and the presence of selected co-morbidities significantly added to the quality of life burden. CONCLUSIONS: Mortality rates and quality of life estimates in DVT patients are below age-adjusted UK estimates. The effect of co-morbidities is significant and limits the potential to draw firm conclusions about the real “net” burden of DVT.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCV60
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders
